atorvastatin has been researched along with lisinopril in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boyacioglu, S; Gur, G; Kanbay, M; Sekuk, H; Yilmaz, U | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Kékes, E | 1 |
| Parker, T | 1 |
| Borlu, M; Dogan, A; Duran, M; Gunebakmaz, O; Heyit, T; Inanc, MT; Kalay, N; Kasapkara, HA; Kaya, MG; Oguzhan, A; Ozdogru, I; Yarlıoglues, M | 1 |
| Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L | 1 |
| Chedgy, F; Howlett, DC; Inglis, C | 1 |
| Danafar, H; Davaran, S; Hamidi, M; Rostamizadeh, K | 1 |
| Bonham, L; Donnelly, RF; Hughes, CM; Quinn, HL | 1 |
| Ekblom, M; Lennernäs, H; Malm-Erjefält, M; Vouis, J; Zdravkovic, M | 1 |
| Carroll, C; Hassanin, A | 1 |
| Mehta, A; Sperling, LS; Wells, BJ | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Fu, Q; He, Z; Li, J; Li, M; Li, W; Liu, X; Song, J; Tian, B | 1 |
| Abdelazeem, B; Barham, W; Khor, SY; Osman, AF | 1 |
| Chen, M; Collu, R; Daley, S; Giunti, E; Xia, W | 1 |
2 review(s) available for atorvastatin and lisinopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
4 trial(s) available for atorvastatin and lisinopril
| Article | Year |
|---|---|
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet's disease.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Behcet Syndrome; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lisinopril; Male; Placebo Effect; Pyrroles; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2010 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Galactose; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Humans; Infant; Lisinopril; Losartan; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antihypertensive Agents; Atorvastatin; Biopharmaceutics; Cardiotonic Agents; Computer Simulation; Cross-Over Studies; Digoxin; Double-Blind Method; Drug Interactions; Female; Gastric Emptying; Gastrointestinal Absorption; Griseofulvin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liraglutide; Lisinopril; Male; Middle Aged; Therapeutic Equivalency; Tissue Distribution; Young Adult | 2015 |
15 other study(ies) available for atorvastatin and lisinopril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Acute pancreatitis associated with combined lisinopril and atorvastatin therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; Humans; Lisinopril; Male; Pancreatitis; Pyrroles | 2005 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Case of the month. Idiopathic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Clopidogrel; Diuretics; Dyspnea; Echocardiography; Electrocardiography; Furosemide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Potassium; Propanolamines; Pyrroles; Spironolactone; Ticlopidine | 2009 |
A case of recurrent ventricular tachycardia.
Topics: Aged; Atorvastatin; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heptanoic Acids; Humans; Isosorbide Dinitrate; Lisinopril; Nitroglycerin; Pyrroles; Recurrence; Tachycardia, Ventricular; Warfarin | 2011 |
PLA-PEG-PLA copolymer-based polymersomes as nanocarriers for delivery of hydrophilic and hydrophobic drugs: preparation and evaluation with atorvastatin and lisinopril.
Topics: Atorvastatin; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hydrophobic and Hydrophilic Interactions; Lisinopril; Nanostructures; Polyesters; Polyethylene Glycols; Polymers; Spectroscopy, Fourier Transform Infrared | 2014 |
Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs.
Topics: Administration, Cutaneous; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Aspirin; Atorvastatin; Cardiovascular Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Delivery Systems; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lisinopril; Microinjections; Platelet Aggregation Inhibitors; Swine | 2015 |
Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atorvastatin; Atrial Fibrillation; Bone Density Conservation Agents; Deprescriptions; Digoxin; Diltiazem; Diuretics; Drug Overdose; Factor Xa Inhibitors; Female; Furosemide; Heart Failure; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Lisinopril; Loratadine; Metoprolol; Polypharmacy; Pyrazoles; Pyridones; Ranitidine; Syncope | 2017 |
Postexercise Ankle-Brachial Index Testing.
Topics: Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Exercise; Exercise Test; Exercise Therapy; Female; Humans; Intermittent Claudication; Lisinopril; Middle Aged; Peripheral Arterial Disease | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
Topics: Atorvastatin; Calorimetry, Differential Scanning; Drug Compounding; Drug Stability; Lisinopril; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2021 |
Recurrent biventricular takotsubo cardiomyopathy with fatal outcome.
Topics: Atorvastatin; Carvedilol; Fatal Outcome; Female; Humans; Lisinopril; Natriuretic Peptide, Brain; Stroke Volume; Takotsubo Cardiomyopathy; Troponin I; Ventricular Function, Left | 2022 |
Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau mice.
Topics: Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Mice; Mice, Transgenic; Proteomics; tau Proteins | 2023 |